Combination therapy aims to boost response in rare skin cancers
NCT ID NCT04256018
First seen Jul 01, 2026 · Last updated Jul 01, 2026
Summary
This trial tests whether combining the drug mogamulizumab with low-dose total skin electron beam therapy works better than either alone for people with mycosis fungoides or Sezary syndrome, two rare types of skin lymphoma. Participants receive both treatments over several weeks. The study measures how many people's cancer shrinks or disappears, and how long that effect lasts.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mogamulizumab and low-dose total skin electron beam therapy
What this could lead to
If successful, this combination could offer a more effective treatment option for people with advanced stages of mycosis fungoides and Sezary syndrome, potentially leading to better disease control.
What could go wrong
This is a small, early-phase study (30 participants) at a single center, so results may not apply broadly. The combination may cause side effects from both the drug and radiation, and it is not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYCOSIS FUNGOIDES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stanford Cancer Center
RECRUITINGStanford, California, 94304, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••